Managing costs and care with biosimilars Biosimilars — a fast-growing class of therapeutic products that are highly similar to and have no clinically meaningful differences from existing FDA-approved branded biologics — are poised to significantly change the face of medicine in oncology, rheumatology, diabetes and many other disease categories. As one of the largest healthcare distributors in the U.S., Cardinal Health has broad access to commercially available biosimilars as well as a deep understanding of the clinical and economic issues related to biosimilars and their reference products. FDA-approved biosimilars HCPCS code FDA-approved biosimilars Biosimilar Approval date Launch date Reference Reference source biologic source Q5107 Mvasi™ (bevacizumab-awwb) Amgen September 2017 July 2019 Avastin Genentech Q5118 Zirabev® (bevacizumab-bvzr) Pfizer June 2019 December 2019 Avastin Genentech Q5105 Retacrit® (epoetin alfa-epbx) Pfizer May 2018 November 2018 Epogen/ Procrit Amgen/ (ESRD on dialysis) Janssen Q5106 (non-ESRD) Q5113 Herzuma® (trastuzumab-pkrb) Teva December 2018 March 2020 Herceptin Genentech Q5117 Kanjinti™ (trastuzumab-anns) Amgen June 2019 July 2019 Herceptin Genentech Q5114 Ogivri® (trastuzumab-dkst) Mylan December 2017 December 2019 Herceptin Genentech Q5112 Ontruzant® (trastuzumab-dttb) Merck January 2019 May 2020 Herceptin Genentech Q5116 Trazimera™ (trastuzumab-qyyp) Pfizer March 2019 February 2020 Herceptin Genentech Q5108 Fulphila® (pegfilgrastim-jmdb) Mylan June 2018 July 2018 Neulasta Amgen Q5122 Nyvepria® (pegfilgrastim-apgf) Pfizer June 2020 December 2020 Neulasta Amgen Q5111 Udenyca® (pegfilgrastim-cbqv) Coherus November 2018 January 2019 Neulasta Amgen Q5120 Ziextenzo® (pegfilgrastim-bmez) Sandoz November 2019 November 2019 Neulasta Amgen Q5110 Nivestym® (filgrastim-aafi) Pfizer July 2018 October 2018 Neupogen Amgen Q5101 Zarxio® (filgrastim-sndz) Sandoz March 2015 September 2015 Neupogen Amgen Q5121 Avsola™ (infliximab-axxq) Amgen December 2019 July 2020 Remicade Janssen Q5103 Inflectra® (infliximab-dyyb) Pfizer April 2016 November 2016 Remicade Janssen Q5104 Renflexis® (infliximab-abda) Merck April 2017 July 2017 Remicade Janssen TBD Riabni™ (rituximab-arrx) Amgen December 2020 January 2021 Rituxan Amgen Q5119 Ruxience® (rituximab-pvvr) Pfizer July 2019 January 2020 Rituxan Genentech Q5115 Truxima® (rituximab-abbs) Teva November 2018 November 2019 Rituxan Genentech TBD Erelzi® (etanercept-szzs) Sandoz August 2016 TBD Enbrel Amgen TBD Eticovo™ (etanercept-ykro) Samsung Bioepis April 2019 TBD Enbrel Amgen TBD Abrilada™ (adalimumab-afzb) Pfizer November 2019 est. 2023 Humira Abbvie TBD Amjevita™ (adalimumab- atto) Amgen September 2016 est. 2023 Humira Abbvie TBD Cyltezo® (adalimumab-adbm) Boehringer August 2017 est. 2023 Humira Abbvie Ingelheim TBD Hadlima™ (adalimumab-bwwd) Merck July 2019 est. 2023 Humira AbbVie TBD Hulio® (adalimumab-fkjp) Mylan July 2020 est. 2023 Humira AbbVie TBD Hyrimoz™ (adalimumab-adaz) Sandoz October 2018 est. 2023 Humira AbbVie TBD Ixifi™ (infliximab-qbtx) Pfizer December 2017 No U.S. launch Remicade Janssen Learn more about our expertise, solutions and access to biosimilars at cardinalhealth.com/biosimilars Source: Applicable manufacturer website Document last updated on Feb. 5, 2021 © 2021 Cardinal Health. All Rights Reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks of Cardinal Health and may be registered in the US and/or in other countries. All other marks are the property of their respective owners. Lit. No. 1SS21-1332615 (02/2021).